NCT00666380View on ClinicalTrials.gov

A Study to Determine the Effects of an Investigational Malaria Vaccine Given to Adults Living in the United States and Thereafter to Adults Living in Kenya

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

December 31, 2008

Study Completion Date

June 30, 2009

Conditions
Malaria
Interventions
BIOLOGICAL

Plasmodium falciparum Malaria Protein 010 (FMP010)

Vaccine antigen is a recombinant protein based on merozoite surface protein-1 (MSP-1) of FVO strain of Plasmodium falciparum, and adjuvant AS01B is a proprietary adjuvant of GSK

Trial Locations (2)

20910

Department of Clinical Trials, WRAIR, Silver Spring

Unknown

USAMRU-K/ KEMRI. Walter Reed Project, Kombewa, Kisumu

Sponsors
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

collaborator

United States Agency for International Development (USAID)

FED

collaborator

Walter Reed Army Institute of Research (WRAIR)

FED

collaborator

Kenya Medical Research Institute

OTHER

lead

U.S. Army Medical Research and Development Command

FED